1The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329, 977-86.
2UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352,837-57.
3UK Prospective Diabetes Study (UI(PDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes {UKPDS 341. Lancet. 1998; 352, 854-65.
4Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes care, 2008; 88, 2977-81.
5Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications, 2005; 19, 198-81.
6Klonoff DC. Continuous glucose monitoring roadmap for 21st century therapy. Diabetes Care, 2005; 28, 1231-9.
7Hirsch JB, Armstrong D, Bergenstal RM, et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther, 2008; 10, 232-44: quiz245-6.
8Arvanitakis Z, Wilson RS, Bieias JL. et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol, 2004; 61, 661-6.
9Yamada M, Kasagi F, Sasaki H, et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc, 2003; 51,43.0-14.
10Leibson CL, Rocca WA, Hanson VA, etal. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol, 1997; 145, 301-8.
